PEP-GHK-CU-KPV • RESEARCH USE ONLY

GHK-Cu / KPV

A dual-action nasal peptide blend combining GHK-Cu, a regenerative copper peptide that supports collagen synthesis and tissue repair, with KPV, a potent anti-inflammatory tripeptide that calms immune signaling and supports gut and skin health. Together, this formulation supports systemic healing, skin rejuvenation, and inflammation balance through complementary pathways.

50 mg / 10 mg

Per Bottle

— 312 mcg / 62 mcg per spray

>99%

Purity

— Third-party verified

160

Sprays per bottle

Protocol & Dosing

Use once daily, either morning or evening. For skin- and inflammation-focused benefits, consistent daily use is recommended.

Starting

624 mcg GHK-Cu + 124 mcg KPV (2 sprays) 1-3x weekly max

Medium

936 mcg GHK-Cu + 186 mcg KPV (3 sprays) 1-3x weekly max

Higher

1,248 mg mcg GHK-Cu + 248 mcg KPV (4 sprays) 1-3x weekly max

Cycles

May be used continuously for up to 3 months
Take 1–2 weeks off every 3 months to allow receptor and pathway reset
KPV can cause excessive immune suppression if used too frequently
This combination is not intended for daily use
Limiting use to 1–3 times per week helps maintain immune balance while still providing skin, gut, and anti-inflammatory benefits

Key Benefits

Enhances skin tone and firmness, reduces redness and irritation, supports gut integrity, calms systemic inflammation, promotes wound and tissue repair, and supports overall skin and immune resilience.

Guidance

Wait at least 30 minutes before or after using other peptides such as BPC-157, TB-500, or additional nasal sprays
Can be combined with BPC-157 protocols for synergistic gut and tissue healing
Start with 2 sprays on the days you use it
Increase gradually only if needed
Use no more than once per day
Do not exceed 4 sprays per day unless directed
Ideal for skin rejuvenation, redness reduction, gut support, and systemic anti-inflammatory balance
Well tolerated and non-stimulatory
Pairs well with BPC-157 and other regenerative peptides when spaced appropriately

PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange

Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.

Dual-polarity solubilization

Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.

Keratin modulation & partitioning

Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).

Superior loading vs. lipid carriers

Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.

>57× vs. saline · <10 nm (DLS)

>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.

Safety, stability & distribution

ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117

Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA